Lucas Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Lucas Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2,033	Closed	-$346K	–	88
2018 Q2	$346K	Buy	2,033 +18	+0.9%	+$2.79K	0.33%	62
2018 Q1	$316K	Hold	2,015	–	–	0.31%	67
2017 Q4	$302K	Hold	2,015	–	–	0.26%	78
2017 Q3	$306K	Sell	2,015 -10	-0.5%	-$1.5K	0.27%	73
2017 Q2	$261K	Sell	2,025 -75	-4%	-$9.03K	0.19%	102
2017 Q1	$230K	Buy	+2,100	New	+$185K	0.17%	101
2016 Q1	–	Sell	-2,150	Closed	-$271K	–	121
2015 Q4	$271K	Hold	2,150	–	–	0.17%	95
2015 Q3	$224K	Buy	2,150 +25	+1%	+$3.21K	0.13%	102
2015 Q2	$262K	Hold	2,125	–	–	0.12%	110
2015 Q1	$251K	Buy	+2,125	New	+$255K	0.1%	110

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Lucas Capital Management's VRTX Position: Q3 2018 in Review

Lucas Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2018, closing a stake of 2,033 shares — an estimated $346K sold.

Lucas Capital Management first reported a position in VRTX in Q1 2015 and held it in 10 quarters. The position peaked at $346K in Q2 2018. 696 funds tracked by Wall St. Rank hold VRTX as of Q3 2018.

Lucas Capital Management reported no remaining Vertex Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Lucas Capital Management sold 2,033 Vertex Pharmaceuticals shares in Q3 2018, an estimated $346K.
Lucas Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2015 and held it in 10 quarters.
Lucas Capital Management's Vertex Pharmaceuticals position peaked at $346K in Q2 2018.
696 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2018.

Based on Lucas Capital Management's 13F filing for Q3 2018, filed 26 Oct 2018.